Public Health - Phenibut Consumer Protection Act (JT Alvey Phenibut Consumer Protection Act)
Summary
HB996 creates the Phenibut Consumer Protection Act and adds a new subtitle to the Health-General Article governing the preparation, sale, labeling, and advertising of phenibut products in Maryland. The bill defines phenibut products and retailers broadly, covering manufacturers, wholesalers, and a wide range of food and retail businesses. It requires retailers that sell phenibut products to disclose the factual basis for any product representations on the label, and it prohibits sale of phenibut products that do not meet the disclosure requirement or that have not been recognized as a dietary ingredient or approved drug by the U.S. Food and Drug Administration.
The bill also bars the sale of phenibut products that are adulterated or contaminated with dangerous substances, or that fail to state the amount of beta-phenyl-gamma-aminobutyric acid HCL on the package or label. Retailers may not sell phenibut products to individuals under 21, may not advertise therapeutic benefits, and may not market phenibut to minors using youth-oriented imagery or in venues and publications with substantial under-21 audiences. The Maryland Department of Health must adopt implementing regulations and, by December 31, 2026, report to the General Assembly on adverse health events associated with phenibut use.
Impact
HB996 amends the Health-General Article by creating enforceable state standards for phenibut products, including labeling, product integrity, age restrictions, advertising limits, and penalties for violations. It authorizes civil penalties, misdemeanor liability, and civil damages for noncompliance, and it requires the Department of Health to promulgate regulations. The bill also directs the Department of Health, working with the Maryland Hospital Association, to collect and report data on adverse health events, which may inform future public health or consumer protection actions affecting retailers, manufacturers, and distributors of phenibut products.
Sentiment
The bill appears to have been broadly supported and noncontroversial in the legislature. It passed the House 137-0 and the Senate 47-0, indicating unanimous approval in both chambers. The lack of recorded committee transcript discussion also suggests there was little visible opposition or extended debate in the available record.
Contention
No specific points of contention are reflected in the available committee materials or voting record. Based on the bill text, any potential concerns would likely center on the scope of the restrictions—especially the age limit, advertising limitations, and the prohibition on products not recognized by FDA as a dietary ingredient or approved drug—but the unanimous votes suggest those issues did not generate significant legislative opposition. The bill’s broad definition of retailer and its criminal and civil penalties could also be sensitive for affected businesses, though no formal objections are shown in the record.